Risk factor hyperlipemia: clinical aspects and therapy
Gries, F.A.
Die Medizinische Welt 26(36): 1590-1597
1975
ISSN/ISBN: 0025-8512 PMID: 1160603 Document Number: 85621
Document emailed within 1 workday
Related Documents
Hashimoto, T.; Kobayashi, M.; Igarashi, H.; Niitani, H. 1975: Hyperlipemia as a risk factor in ischemic heart disease Nihon Rinsho. Japanese Journal of Clinical Medicine 33(11): 3179-3184Turcanu, V.; Bartl, F.; Fiat, F. 1970: Clinical and biological aspects of hyperlipemia Medicina Interna 22(4): 489-493
Prichard, B.N. 1990: Pharmacological and clinical aspects of drug therapy in coronary heart disease: clinical aspects of therapy with beta-adrenoceptor antagonists Zeitschrift für Kardiologie 79(Suppl 3): 99-103
Tayeau, F.; Jouzier, E.; Tixier, M. 1970: Research on experimental hyperlipemia. 3. Action "in vivo" of the inhibitor of the clarifying factor Bordeaux Medical 3(9): 2011-2014
Tayeau, F.; Jouzier, E.; Tixier, M. 1970: Research on experimental hyperlipemia. II. Isolation and "in vitro" study of a natural inhibitor of the clarifying factor Bordeaux Medical 3(9): 1999-2008
Robles Gil, J.; Armas, C. 1978: Various epidemiological aspects of hyperuricemia and gout in Mexico: incidence and the cardiovascular risk factor Archivos del Instituto de Cardiologia de Mexico 48(6): 1121-1141
Zulić, I.; Stanković, D.; Mulabegović, N.; Serdarević, D. 1978: Prevalence of hyperlipemia above the risk margin in laborers and clerical workers Medicinski Arhiv 32(3): 145-154
Baule, G.M.; Lo Dico, G.; Schonauer, S. 1976: A case of mixed hyperlipemia in the umbilical cord blood. Importance of genetic and preventive aspects of this finding La Nouvelle Presse Medicale 5(30): 1916
De Gennes, J.L.; Turpin, G.; Truffert, J.; Labrousse, B. 1972: Corrective therapy of atherogenic hyperlipemia Acta Cardiologica 1972: Suppl 15: 115-113
Jansen, S.; Zambrana, J.L.; López Miranda, J.; Blanco, A.; Blanco, J.; Jiménez Perepérez, J.A.; Espino, A.; Pérez Jiménez, F. 1995: Possible relationship between overweightness and prevalence of hyperlipemia in the children of patients with heterozygote familial hypercholesterolemia and combined familial hyperlipemia Medicina Clinica 105(3): 85-88
Karges, H.E.; Clemens, R. 1988: Factor XIII: enzymatic and clinical aspects Behring Institute Mitteilungen 82: 43-58
Dölle, W.; Daiss, W. 1988: Therapy of chronic inflammatory bowel diseases. Clinical aspects and therapy of drug-induced side effects Verhandlungen der Deutschen Gesellschaft für Innere Medizin 94: 184-191
Nicolaisen, E.M.; Hansen, L.L.; Poulsen, F.; Glazer, S.; Hedner, U. 1996: Immunological aspects of recombinant factor VIIa (rFVIIa) in clinical use Thrombosis and Haemostasis 76(2): 200-204
Roberts, H.R. 1998: Clinical experience with activated factor VII: focus on safety aspects Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 9(Suppl 1): S115-S118
Cohen, P.; Fielder, P.J.; Hasegawa, Y.; Frisch, H.; Giudice, L.C.; Rosenfeld, R.G. 1991: Clinical aspects of insulin-like growth factor binding proteins Acta Endocrinologica 124(Suppl): 74-85
Celle, G. 1987: Clinical aspects and therapy of ascites. Medical therapy Minerva Medica 78(10): 659-662
Laurell, K.; Lundström, E. 2012: Migrainous infarction: aspects on risk factors and therapy Current Pain and Headache Reports 16(3): 255-260
Andersen, K.S.; Johannessen, H. 1974: Gas transfer factor. Clinical and physiological aspects in changes of the lung diffusion capacity Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 94(25): 1527-1530
Arteaga, A.; Foradori, A.; Eyzaguirre, J.; Lira, P.; Vasquez, A.; Soto, S.; Alliende, M.E.; Guzman, L. 1970: Clinical evaluation of a new drug (CH 13437) in the treatment of hyperlipemia Revista Medica de Chile 98(10): 689-694
Colombo, L.; Monarca, A.; Goldberg, D.; Zanetta, R. 1979: Tolerability and side-effects of bis-(hydroxy-2-ethylthio)-1,10-decane (BS 530) as compared with clofibrate in the therapy of hyperlipemia La Clinica Terapeutica 91(2): 155-171